GlobeNewswire by notified

Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02

Share

COPENHAGEN, Denmark, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced promising clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02.

In the clinical study, EVX-02 is given in combination with a checkpoint inhibitor and targets cancer mutations, neoantigens, in patients with resected melanoma. The Company reported encouraging interim safety and immunogenicity data from the Phase 1/2a study of its personalized DNA-based immunotherapy, EVX-02. The results are summarized below.

“We are thrilled to announce promising interim data from the first eight patients in our Phase 1/2a study of EVX-02. We believe that these results serve as validation of our DNA technology for personalized cancer immunotherapy. All patients demonstrated a specific T-cell immune response induced by the treatment, confirming the potential capabilities of our AI platform technology. And importantly, the treatment appeared to be well tolerated in all patients, with only very mild adverse events (AEs) observed,” said CEO Per Norlén.

Personalized cancer immunotherapy, like EVX-02, is particularly challenging to produce because a new and unique drug is manufactured for each patient.

“This is a tremendous achievement. Our team has successfully completed this complex process, from biopsy, through genome sequencing, a selection of the most promising cancer targets through our AI platform technology, to manufacturing, quality testing, and drug product production and delivery. And they succeeded with every single step for each patient,” says Mr. Norlén.
“The promising EVX-02 data, demonstrating both proof of mechanism and an encouraging safety profile, give us exactly what we need for our upcoming clinical trial of EVX-03 and our next-generation DNA technology.”

Interim results in summary:

  • Safety: Treatment appeared to be well tolerated in all patients, with only very mild adverse events (AEs) observed in relation to EVX-02 treatment.
  • EVX-02 induced CD4+ and CD8+ specific T-cell responses in all patients, providing proof of mechanism for our DNA-delivery technology, in that the delivered EVX-02-DNA gave rise to immune reactions to its encoded neoantigen peptides.
  • The T-cell responses were robust and long-lasting.

A full clinical trial report for the EVX-02 Phase 1 study is expected in the second quarter of 2023.

About Evaxion
Evaxion Biotech A/S is a clinical-stage biotech company developing AI-powered immunotherapies. A proprietary and scalable AI technology is used to decode the human immune system to discover and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has a broad pipeline of novel product candidates, including patient-specific cancer immunotherapies. It is located in Hørsholm, Denmark, with 70 employees.

Evaxion Biotech A/S
Per Norlén
Chief Executive Officer (CEO)

For more information, please contact
Katrine Hertz Mortensen
VP, Communications and Public Relations
khm@evaxion-biotech.com
+45 3010 0203

Source: Evaxion Biotech

Forward-looking statement

This announcement contains forward-looking statements that involve substantial risks and uncertainties. All statements, besides those of historical facts, included in this announcement regarding the Company’s future operations, plans and objectives are forward-looking. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; risks associated with the Company’s development work; cost and success of the Company’s product development activities and preclinical and clinical trials; risks related to commercializing any approved pharmaceutical product developed using the Company’s AI platform technology, including the rate and degree of market acceptance of the Company’s product candidates; risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture; risks associated with the Company’s inability to enter into partnerships; risks related to government regulation; risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s ADSs and ordinary shares, risks associated with the pandemic caused by the coronavirus known as COVID-19 and the emergence and prevalence of COVID-19 variants, such as the Delta and Omicron variant and certain related variants such as the Omicron BA.4 and BA.5 variants, risks associated with the invasion of the Ukraine by Russia and other risks and uncertainties affecting the Company’s business operations and financial condition.

Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, see the risks described in the “Risk Factors” section included in the Company’s Annual Report on Form 20-F filed on March 31, 2022 and the Company’s current and future reports filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this announcement speak only as of the date hereof, and except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Correction: AB Linas Agro Group investors calendar for the 20232.12.2022 08:00:43 CET | Press release

A list of key information disclosure dates in 2023: February 28, 2023Interim half-year unaudited report for FY 2022/2023.March 1, 2023Investor Conference Webinar to introduce unaudited financial and activity results for the half-year of FY 2022/2023.May 31, 2023Interim unaudited report for 9 months of FY 2022/2023.June 1, 2023Investor Conference Webinar to introduce unaudited financial and activity results for 9 months of FY 2022/2023.August 31, 2023Interim unaudited report for 12 months of FY 2022/2023.September 4, 2023Investor Conference Webinar to introduce unaudited financial and activity results for 12 months of FY 2022/2023.Week 40 (Oct 2-6, 2023)Notice on Annual General Meeting of shareholders.Week 43 (Oct 23-27, 2023)Resolutions of the Annual General Meeting of shareholders and Annual audited results for FY 2022/2023.November 30, 2023Interim unaudited report for 3 months of 2023/2024 financial year.December 1, 2023Investor Conference Webinar to introduce unaudited financial and

PRESS RELEASE: NACON UNVEILS THE MG-X PRO MADE FOR iPHONE®2.12.2022 08:00:00 CET | Press release

NACON UNVEILS THE MG-X PRO MADE FOR iPHONE® Lesquin, 2 December 2022 – The premium gaming accessories designer NACON is pleased to announce the launch of its new MG-X Pro Made For iPhone® controller. The officially licensed Xbox MG-X Pro Made For iPhone® cloud-gaming controller is the ideal controller for subscribers to Xbox Game Pass Ultimate™. Like the MG-X Pro for Android, which has won critical acclaim since its release in January 2022, the MG-X Pro Made For iPhone® provides all the classic controls of an Xbox controller for cloud gaming on mobile with Game Pass Ultimate™ and with any compatible game in the Apple Store. The MG-X Pro Made for iPhone® is compatible with a wide range of iPhone® models, from the 6S to the latest, thanks to its adjustable holder and Bluetooth® connectivity. The MG-X Pro Made For iPhone® connects to your iPhone® in mere seconds and lets you play all games available in Xbox Game Pass Ultimate™. The ergonomic handles, asymmetric sticks, bumpers, triggers,

KBC Group: KBC Bank Ireland welcomes decision of Minister for Finance to approve the sale of substantially all of its performing loan assets and liabilities to Bank of Ireland Group2.12.2022 08:00:00 CET | Press release

Press Release Outside trading hours – Regulated information* Brussels, 2 December 2022 (8 a.m. CET, before Brussels stock exchange hours) KBC Bank Ireland welcomes decision of Minister for Finance to approve the sale of substantially all of its performing loan assets and liabilities to Bank of Ireland Group. On the 16th of April 2021, KBC Group announced that KBC Bank Ireland had entered into a Memorandum of Understanding (MoU) with Bank of Ireland Group. On the 22nd of October 2021 KBC Bank Ireland entered into a legally binding agreement with Bank of Ireland Group whereby it would acquire substantially all of KBC Bank Ireland’s performing loan assets and deposits. In addition, a small portfolio of non-performing mortgages (NPEs) will also be acquired as part of the transaction. On the 24th of May 2022 the transaction received approval from the Irish Competition and Consumer Protection Commission (CCPC), and today, 2 December 2022, KBC can confirm that the deal received final approval

Mining sector puts energy into ESG, but lacks focus on gender and diversity2.12.2022 08:00:00 CET | Press release

Demand for greater transparency fuels shift in sustainable approach, finds new survey LONDON, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Energy efficiency has soared up the list of environmental priorities for the mining industry and now features in the top three for most companies, along with air and water pollution and waste management. It’s one of the key findings from a survey of global mining sector decision-makers published today by mining executive search and recruitment consultants, Stratum International, and independent ESG accreditors, Digbee. Tackling climate change and biodiversity loss come lower on the list of environmental, social and governance (ESG) factors for many mining businesses, according to the new report. And there’s a concerning lack of focus on gender and diversity for a sector which needs to change the perception that mining is a male-only environment. The issue is deemed the “least important” social priority for mining companies over the next two years. Will Coetzer

Press Release: Statement from Sanofi regarding: rule 2.12 of the takeover rules2.12.2022 07:55:00 CET | Press release

THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.12 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE "TAKEOVER RULES"). NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. DECEMBER 2, 2022 Statement from Sanofi regarding: rule 2.12 of the takeover rules Paris, December 2, 2022. As required by Rule 2.12 of the Takeover Rules, Sanofi S.A. (“Sanofi”) confirms that any offer for Horizon Therapeutics plc, if made by Sanofi, will be solely in cash. There is no certainty that any offer will be made, nor as to the terms on which any such offer may be made, if forthcoming. About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible